FTC prepares to block Amgen’s $28.3bn deal for Horizon Therapeutics
The US Federal Commerce Fee will sue to dam Amgen’s $28.3bn deal to amass Horizon Therapeutics, in line with an individual aware of the matter.
The lawsuit, which is about to be filed on Tuesday, would mark the primary time in additional than a decade that the FTC has sought to dam a deal within the pharmaceutical sector.
FTC chair Lina Khan is amongst a brand new cohort of progressive antitrust officers appointed by US president Joe Biden, who’ve vowed to undertake a harder stance and crack down on anti-competitive conduct within the US.
Shares in Horizon, which relies in Eire, had been down greater than 17 per cent in pre-market commerce. The information additionally appeared to hit Seagen, which was down 5.6 per cent in pre-market commerce as traders weighed the opportunity of the FTC focusing on different offers within the sector. The oncology-focused biotech agreed a $43bn deal in March to be acquired by Pfizer.
The transfer was first reported by Bloomberg.
Further reporting by Peter Wells in New York